Drug Profile
Research programme: antiviral vaccines - Integrated BioTherapeutics/Integral Molecular
Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Integral Molecular; Integrated BioTherapeutics
- Class Antivirals; Viral envelope proteins; Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections; Zika virus infection
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Parenteral)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Zika-virus-infection in USA (Parenteral)
- 02 Nov 2021 Antiviral vaccines are still in preclinical development for Ebola virus infections and Zika virus infections in USA